Shares of Sanofi SA (EPA:SAN) have earned an average recommendation of “Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is €88.80 ($103.26).

A number of brokerages recently weighed in on SAN. Sanford C. Bernstein set a €95.00 ($110.47) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Bank of America set a €100.00 ($116.28) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Friday, September 13th. Credit Suisse Group set a €94.00 ($109.30) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Friday, October 4th. Deutsche Bank set a €92.00 ($106.98) price target on shares of Sanofi and gave the company a “buy” rating in a research report on Monday, September 2nd. Finally, JPMorgan Chase & Co. set a €81.00 ($94.19) price target on shares of Sanofi and gave the company a “neutral” rating in a research report on Tuesday, July 30th.

Shares of EPA:SAN opened at €82.67 ($96.13) on Friday. The company has a 50 day moving average price of €80.96. Sanofi has a fifty-two week low of €63.09 ($73.36) and a fifty-two week high of €92.97 ($108.10).

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: What is dollar cost averaging (DCA)?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.